| Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) (NCT05270668) | Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2022-03-29 |
| Effectiveness of Bosentan Therapy in Patients With Systemic scleRosis and Progressive Digital ulcEr Disease. (NCT05168215) | Elpen Pharmaceutical Co. Inc. | 2022-01-01 |
| A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis (NCT05098145) | Talaris Therapeutics Inc. | 2021-11-24 |
| A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) (NCT04478994) | Amgen | 2021-11-17 |
| A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis (NCT04781543) | Amgen | 2021-11-05 |
| A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients (NCT04837131) | Michael M. Pham | 2021-04-28 |
| Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis (NCT04680975) | Kadmon, a Sanofi Company | 2021-03-03 |
| Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis (NCT04440592) | Tanabe Pharma America, Inc. | 2021-02-05 |
| Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc) (NCT04138485) | CSL Behring | 2019-12-20 |
| Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc) (NCT04137224) | CSL Behring | 2019-09-19 |
| KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis (NCT03919799) | Kadmon, a Sanofi Company | 2019-06-26 |
| Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis (NCT03198689) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2019-05-07 |
| Brentuximab Vedotin for Systemic Sclerosis (NCT03222492) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-09-20 |
| Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis (NCT02503644) | Inventiva Pharma | 2015-10-29 |
| Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis (NCT02465437) | Corbus Pharmaceuticals Inc. | 2015-08-01 |
| A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis (NCT02161406) | Dinesh Khanna, MD, MS | 2014-09-01 |
| Mycophenolate Mofetil in Systemic Sclerosis (NCT00433186) | Boston University | 2006-03-01 |